blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3538109

EP3538109 - MDA-7 CANCER THERAPIES AND METHODS OF DETECTING BIOMOLECULES [Right-click to bookmark this link]
StatusThe application is deemed to be withdrawn
Status updated on  04.06.2021
Database last updated on 02.11.2024
FormerRequest for examination was made
Status updated on  16.08.2019
FormerThe international publication has been made
Status updated on  18.05.2018
Most recent event   Tooltip04.06.2021Application deemed to be withdrawnpublished on 07.07.2021  [2021/27]
Applicant(s)For all designated states
Virginia Commonwealth University
800 East Leigh Street
Suite 3000
Richmond, VA 23298 / US
[2019/38]
Inventor(s)01 / FISHER, Paul B.
7 Runswick Drive
Henrico VA 23238 / US
02 / PRADHAN, Anjan K.
800 East Leigh Street Suite 3000
Richmond VA 23298 / US
03 / BHOOPATHI, Praveen
800 East Leigh Street Suite 3000
Richmond VA 23298 / US
04 / DAS, Swadesh
800 East Leigh Street Suite 3000
Richmond VA 23298 / US
05 / EMDAD, Luni
800 East Leigh Street Suite 3000
Richmond VA 23298 / US
 [2019/38]
Representative(s)HGF
HGF Limited
1 City Walk
Leeds LS11 9DX / GB
[N/P]
Former [2019/38]HGF Limited
4th Floor
Merchant Exchange
17-19 Whitworth Street West
Manchester M1 5WG / GB
Application number, filing date17869274.514.11.2017
[2019/38]
WO2017US61527
Priority number, dateUS201662421484P14.11.2016         Original published format: US 201662421484 P
[2019/38]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2018089995
Date:17.05.2018
Language:EN
[2018/20]
Type: A1 Application with search report 
No.:EP3538109
Date:18.09.2019
Language:EN
The application published by WIPO in one of the EPO official languages on 17.05.2018 takes the place of the publication of the European patent application.
[2019/38]
Search report(s)International search report - published on:US17.05.2018
(Supplementary) European search report - dispatched on:EP29.05.2020
ClassificationIPC:C12Q1/68, A61K38/17, A61P35/00, G01N33/574, A61K45/06, C07K14/00, A61K31/7088, C12Q1/6886
[2020/27]
CPC:
A61P35/00 (EP); C12Q1/6886 (EP,US); A61K31/7088 (EP,US);
A61K38/1709 (EP,US); A61K45/06 (EP); C12Q1/686 (US);
G01N33/574 (EP); C07K14/51 (EP); C07K14/54 (EP);
C07K14/705 (EP); C07K14/8146 (EP); C12Q2531/113 (US);
C12Q2561/113 (US); C12Q2600/106 (EP,US); C12Q2600/158 (EP,US);
C12Q2600/178 (EP,US) (-)
Former IPC [2019/38]A61K31/7088, A61K38/17, A61P35/00, C07H21/00
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2019/38]
TitleGerman:MDA-7-KREBSTHERAPIEN UND VERFAHREN ZUM NACHWEIS VON BIOMOLEKÜLEN[2019/38]
English:MDA-7 CANCER THERAPIES AND METHODS OF DETECTING BIOMOLECULES[2019/38]
French:THÉRAPIES ANTICANCÉREUSES À BASE DE MDA-7 ET PROCÉDÉS DE DÉTECTION DE BIOMOLÉCULES[2019/38]
Entry into regional phase28.05.2019National basic fee paid 
28.05.2019Search fee paid 
28.05.2019Designation fee(s) paid 
28.05.2019Examination fee paid 
Examination procedure28.05.2019Examination requested  [2019/38]
03.01.2020Amendment by applicant (claims and/or description)
12.01.2021Application deemed to be withdrawn, date of legal effect  [2021/27]
08.02.2021Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time  [2021/27]
Fees paidRenewal fee
27.11.2019Renewal fee patent year 03
27.11.2020Renewal fee patent year 04
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[XY]WO2004078124  (UNIV TEXAS [US], et al) [X] 13-15 * see claims and examples * [Y] 1-15;
 [IP]  - ANJAN K. PRADHAN ET AL, "mda-7/IL-24 Mediates Cancer Cell-Specific Death via Regulation of miR-221 and the Beclin-1 Axis", CANCER RESEARCH, US, (20161209), vol. 77, no. 4, doi:10.1158/0008-5472.CAN-16-1731, ISSN 0008-5472, pages 949 - 959, XP055695727 [IP] 1-13 * the whole document *

DOI:   http://dx.doi.org/10.1158/0008-5472.CAN-16-1731
 [T]  - M ACUNZO ET AL, "miR-130a targets MET and induces TRAIL-sensitivity in NSCLC by downregulating miR-221 and 222", ONCOGENE, (20110627), doi:10.1038/onc.2011.260, ISSN 0950-9232, XP055097574 [T] * the whole document *

DOI:   http://dx.doi.org/10.1038/onc.2011.260
 [XY]  - DENT P ET AL, "The development of MDA-7/IL-24 as a cancer therapeutic", PHARMACOLOGY AND THERAPEUTICS, ELSEVIER, GB, vol. 128, no. 2, ISSN 0163-7258, (20101101), pages 375 - 384, (20100821), XP027338770 [X] 13-15 * the whole document * [Y] 1-15
 [Y]  - MARIA DI MARTINO ET AL, "In vitro and in vivo anti-tumor activity of miR-221/222 inhibitors in multiple myeloma.", ONCOTARGET JAN 2012, (20130201), vol. 4, no. 2, doi:10.18632/oncotarget.820, ISSN 1949-2553, pages 242 - 255, XP055075966 [Y] 1-12 * abstract *

DOI:   http://dx.doi.org/10.18632/oncotarget.820
 [Y]  - TEIXEIRA ANA L ET AL, "Higher circulating expression levels of miR-221 associated with poor overall survival in renal cell carcinoma patients", TUMOR BIOLOGY, KARGER, BASEL, CH, vol. 35, no. 5, doi:10.1007/S13277-013-1531-3, ISSN 1010-4283, (20131231), pages 4057 - 4066, (20131231), XP036267341 [Y] 1-15 * abstract *

DOI:   http://dx.doi.org/10.1007/s13277-013-1531-3
 [Y]  - CHUNZHI ZHANG ET AL, "High level of miR-221/222 confers increased cell invasion and poor prognosis in glioma", JOURNAL OF TRANSLATIONAL MEDICINE, BIOMED CENTRAL, (20120608), vol. 10, no. 1, doi:10.1186/1479-5876-10-119, ISSN 1479-5876, page 119, XP021126769 [Y] 1-15 * abstract *

DOI:   http://dx.doi.org/10.1186/1479-5876-10-119
 [Y]  - BINGYUAN FEI ET AL, "Expression and clinical significance of Beclin-1 in gastric cancer tissues of various clinical stages", ONCOLOGY LETTERS, GR, (20160204), vol. 11, no. 3, doi:10.3892/ol.2016.4183, ISSN 1792-1074, pages 2271 - 2277, XP055696283 [Y] 1-15 * abstract *

DOI:   http://dx.doi.org/10.3892/ol.2016.4183
International search[XY]US2009186015  (LATHAM GARY J [US], et al) [X] 1, 2, 4, 5, 10, 11, 13-15, 23, 24 * Abstract; Claim 1; Claim 2; Claim 12; Claim 21; Claim 23; para [0081]; para [0087]; para [0090]; para [0092]; para [0098]; para [0176]; para [0204] * [Y] 3, 6-9, 12, 16-22, 30-32;
 [Y]US2008193943  (MURRAY WILLIAM E [US]) [Y] 3, 12, 27, 36 * Abstract; para [0052] *;
 [Y]US2013287772  (HALBERT DAVID D [US], et al) [Y] 9, 16-20, 33, 40-44 * Abstract; para [0020];para [0383] *;
 [Y]US2013267575  (SAFE STEPHEN [US], et al) [Y] 21, 22, 45, 45 * Abstract; Claim 8; para [0003] *;
 [Y]US2011301091  (GIULIANI GIAMMARIA [IT], et al) [Y] 17, 41 * Claim 18; para [0002]; para [0050] *;
 [Y]US2012252023  (CROCE CARLO M [US]) [Y] 18, 42 * Abstract; para [0035]; para [0076] *;
 [Y]  - BHU A et al., "Mechanism of Autophagy to Apoptosis Switch Triggered in Prostate Cancer Cells by Antitumor Cytokine Melanoma Differentiation-Associated Gene 7/lnterleukin-24", Cancer Res., (20100501), vol. 70, no. 9, pages 3667 - 3676, XP055483938 [Y] 6-8, 25-48 * . Abstract; p3671. Figure 3 legend; p3668, col 2, para 4 *

DOI:   http://dx.doi.org/10.1158/0008-5472.CAN-09-3647
 [Y]  - TONG et al., "Intratumoral Injection of INGN 241, a Nonreplicating Adenovector Expressing the Melanoma-Dlfferentiation Associated Gene -7 (mda-7/ IL 24): Biologic Outcome in Advanced Cancer Patients", MOLECULAR THERAPY, (20050100), vol. 11, no. 1, pages 160 - 172, XP004672538 [Y] 25-48 * . Abstract; p170, col 2, para 4; p171, col 1, para 1-2; p171, col 2, para 4 *

DOI:   http://dx.doi.org/10.1016/j.ymthe.2004.09.021
 [Y]  - FALKENBERG et al., "Secreted uPAR isoform 2 (uPAR7b) is a novel direct target of miR-221", Oncotarget, (20150000), vol. 6, no. 10, pages 8103 - 8114, XP055228356 [Y] 20, 44 * . Abstract *

DOI:   http://dx.doi.org/10.18632/oncotarget.3516
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.